Language
In 2025, climb to the "new".Say goodbye to 2024 and look forward to 2025. The company has done a lot of exploration in the combination of stem cells and immune cells. It is our consistent pursuit to let terminal cancer patients get a new life, gain health and achieve happiness. Move towards the "new" and strive forward!
The CGCS Awards ceremony was held at the 5th International Cell & Gene Therapy China Summit & Exhibition 2024. Jiangsu Celltech Medical Research Institute won the "Cell Therapy R&D" Rising Star Award at the ceremony!
Medical enterprises jointly build a scientific innovation platform——Jiangsu Celltech Medical Research Institute signed a scientific research cooperation agreement with Taizhou Second People's Hospital.
From May 22nd to 24th, 2024, the 5th International Cell and Gene Therapy China Summit & Exhibition (CGCS 2024) was grandly held at Nanjing Yangtze River International Conference Center. Professor Yang Meijia of Jiangsu Celltech Medical Research Institute was invited to attend the CGCS summit as a major guest of the main forum.
Recently, the Jiangsu Provincial Department of Human Resources and Social Security announced the "List of New Postdoctoral Innovation Practice Bases in Jiangsu Province in 2022-2023", and Jiangsu Celltech Medical Research Institute was approved as the "Postdoctoral Innovation Practice Base in Jiangsu Province".
On February 29, the Jiangsu Provincial Department of Industry and Information Technology held a special event for the upstream and downstream docking of the gene and cell therapy industry chain in Jiangning District, Nanjing. Representatives from the Provincial Department of Industry and Information Technology, the Provincial Food and Drug Administration, the Municipal Bureau of Industry and Information Technology, the Jiangning District Bureau of Industry and Information Technology, and representatives from Jinsirui Biotech, Chuanqi Biotech,Celltech Medical Research Institute , Nanjing EnruiKainuo Biotech, Nanjing Rongjiekang Biotech, Heqirui Pharmaceutical, Yingshi Biotech and other enterprises attended the event.
At the beginning of January 2024, Nanjing TV interviewed Jiangsu Celltech Medical Research Institute , Executive Vice President Liu Yongjun said: I believe that the innovation environment in Nanjing will get better and better in the future, and I am full of confidence in the future development.
On December 22, the first batch of new R&D institutions established in Nanjing, the laboratory of Scientists are busy modifying and expanding patients' immune cells so that they can be infused back into patients to accurately kill tumor cells.
Jiangsu Celltech Medical Research Institute is the first batch of new R&D institutions established in our city. Its self-developed "tumor microenvironment target E new structure TCR fusion CAR cell therapy technology" has effectively overcome the limitations of cell therapy in the treatment of solid tumors, and has now entered the investigator's clinical trial stage, and is expected to be marketed in Nanjing in three years, with an annual revenue of up to 1 billion yuan.
Liu Yongjun, director and executive vice president of Jiangsu Celltech Medical Research Institute, said that since its establishment, the institute has been positioned to develop international high-quality cell drugs and protein drugs, and has obtained nearly 10 innovative technologies with its own intellectual property rights that have reached the international level, and 3 global first-class innovative drug candidates have entered or will soon enter clinical trials.